Biotech Report: Sektor konsolidiert - Evotec und Qiagen tiefrot | (shareribs.com) Frankfurt / New York 20.09.2024 - Mit teils deutlichen Verlusten präsentierten sich die Biotech-Aktien im deutschen Handel. Für Evotec ging es um mehr als fünf Prozent nach unten. Ein... ► Artikel lesen |
Neue 7,75% Aktienanleihe mit Barriere auf QIAGEN in Zeichnung | München (www.anleihencheck.de) - Die Experten vom Zertifikate-Team der Bank Vontobel Europe AG bieten eine neue Aktienanleihe (ISIN DE000VC3CHU3/ WKN VC3CHU) mit Barriere auf die Aktie von QIAGEN (ISIN... ► Artikel lesen |
QIAGEN N.V.: QIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platform | Venlo, the Netherlands, Sept. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an important milestone with the launch of 100 new assays for its digital... ► Artikel lesen |
Eliem Therapeutics, Inc.: Eliem Therapeutics Reports Second Quarter Financial Results | Eliem completed the acquisition of Tenet Medicines and concurrent $120 million private placement Eliem to host an Investor Day later in the year to provide an overview of budoprutug (previously referred... ► Artikel lesen |
Eliem Therapeutics, Inc.: Eliem Therapeutics Announces its Addition to the Russell 2000 and Russell 3000 Indexes | SEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today that the Company will be included in the Russell 2000® Index and the... ► Artikel lesen |
Eliem Therapeutics, Inc.: Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement | Eliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy... ► Artikel lesen |
Arvinas Inc.: Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer | - Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology... ► Artikel lesen |
Arvinas, Pfizer, Report 6-month Follow Up Data From Phase 1b Study Of Vepdegestrant+Palbociclib | NEW YORK CITY (dpa-AFX) - Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) Thursday announced positive 6-month follow up data from a Phase 1b study evaluating vepdegestrant in combination with Pfizer's... ► Artikel lesen |
Arvinas Inc.: Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE) | - After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combination... ► Artikel lesen |